Related Experiment Video
Updated: Apr 22, 2026

Experimental Model to Evaluate Resolution of Pneumonia
Published on: February 17, 2023
Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children
A Wrotek1, T Jackowska, K Pawlik
1Department of Pediatrics, Medical Center of Postgraduate Education, 99/103 Marymoncka St., Warsaw, 01-813, Poland.
Insights
Soluble urokinase plasminogen activator receptor (suPAR) levels are higher in children with pneumonia, indicating potential as a biomarker for disease severity and immune system activation.
Area of Science:
- Pediatrics
- Immunology
- Biomarkers
Background:
- Soluble urokinase plasminogen activator receptor (suPAR) is linked to immune system activation.
- Limited data exist on suPAR as a biomarker for pneumonia severity.
Purpose of the Study:
- To determine suPAR levels in hospitalized children with community-acquired pneumonia (CAP).
- To correlate suPAR levels with CAP severity.
- To compare suPAR levels between children with and without pneumonia.
Main Methods:
- Study included 596 children (447 with pneumonia, 119 healthy).
- suPAR levels measured in pneumonia patients and healthy controls.
- CAP severity assessed using clinical and laboratory indicators.
Main Results:
- Children with pneumonia had significantly higher suPAR levels (median 7.11 ng/mL) than healthy children (4.68 ng/mL).
- suPAR correlated positively with fever, time to defervescence, hospital stay, CRP, and procalcitonin.
- suPAR levels were higher in severe CAP cases.
- suPAR correlated inversely with sodium and saturation.
Conclusions:
- Elevated suPAR levels are observed in pediatric pneumonia.
- suPAR may serve as a valuable biomarker reflecting pneumonia severity in children.
Abstract:
Enhanced level of soluble urokinase plasminogen activator receptor (suPAR) level has been associated with activation of the immune system. It may be a novel biomarker for pneumonia severity, yet data on this subject are limited. In the present study we seek to determine the suPAR level in hospitalized children with community-acquired pneumonia (CAP), its correlation with pneumonia severity, and to compare the suPAR level between pneumonia and healthy conditions. The study encompassed a total of 596 children: 447 with pneumonia and 119 healthy. suPAR was measured in 227 out of the 447 pneumonia patients and in all healthy subjects. We used clinical indicators (fever, time for defeverscence, heart and breath rate, saturation, and length of antibiotic treatment and of hospitalization) and laboratory indicators (CRP, procalcitonin, white blood cell count, and sodium) to assess the CAP severity. The finding were that the suPAR concentration in children with pneumonia was significantly higher (median 7.11 ng/mL) than in healthy individuals (4.68 ng/mL). We found a positive correlation between the suPAR and the following factors: fever, time for defeverscence, length of hospital stay, and elevated CRP and procalcitonin levels. There was a reverse correlation with sodium concentration and capillary blood saturation. Moreover, the suPAR level was significantly higher in children with a severe course of pneumonia compared with those having non-severe pneumonia (7.79 vs. 6.87 ng/mL; p = 0.006). In conclusion, suPAR elevation is observed in pneumonia and may reflect its severity.
More Related Videos
06:05Using the Overlay Assay to Qualitatively Measure Bacterial Production of and Sensitivity to Pneumococcal Bacteriocins
Published on: September 30, 2014
11:32Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Related Concept Videos
Pneumonia III: Complications and Assessment
Pneumonia I: Introduction
Atypical Pneumonia
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: